• Andrew Miller has been named senior VP and CFO of Cepheid (Sunnyvale, California), effective April 14. Miller previously was VP and chief accounting officer at autodesk. Cepheid makes integrated systems for genetic analysis for the clinical, industrial and biothreat markets.

• ev3 (Plymouth, Minnesota) reported the resignation of John Simpson from his position as chief scientist and from the company’s board, effective Feb. 7. “Over the last 30 years, few people have shaped the treatment of cardiovascular disease as much as Dr. John Simpson with his numerous inventions and vision for improving the lives of patients worldwide,” said Jim Corbett, president/CEO and chairman of ev3. “He leaves a legacy of innovation and a foundation on which we intend to build in our effort to improve patient treatment.” With the resignation of Simpson, the ev3 board of directors has nine members, of which six are independent directors. ev3 is a developer of endovascular therapies.

• Michael Beland has been named corporate controller of OrthoSynetics (Metairie, Louisiana). Previously, Beland was the director of accounting research and policy for the Shaw Group. OrthoSynetics makes orthodontic and dental products.